Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab (UST) is an antibody to the p40 subunit of interleukins 12 and 23 in Crohn's disease (CD) patients.
|
31722356 |
2020 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The approval of ustekinumab, a monoclonal antibody blocking the common p40 subunit of IL12 and IL23, marked an important evolution in medical management for CD: this novel class of biologic therapy demonstrated efficacy in both patients naïve to biologics as well as in patients experiencing inadequate response or loss of response to TNF antagonists.
|
31327402 |
2019 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The monoclonal antibody targeting the shared p40 subunit of IL-12 and IL23, namely ustekinumab, has been approved for Crohn's disease (CD) and has demonstrated promising results in the treatment of ulcerative colitis.
|
30884245 |
2019 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab and briakinumab are monoclonal antibodies that target the standard p40 subunit of cytokines interleukin-12 and interleukin-23 (IL-12/23p40), which are involved in the pathogenesis of Crohn's disease (CD).
|
31828765 |
2019 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistently, neutralizing antibodies against IL-12/IL-23 p40 and IL-23 p19 have been successfully used in clinical trials for therapy of Crohn´s disease and pilot studies in ulcerative colitis are ongoing.
|
30563755 |
2019 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab is a monoclonal antibody that binds with high affinity to the p40 subunit of human interleukin 12 (IL12 and IL23) that has been approved for treatment of patients with moderate to severe Crohn's disease (CD).
|
29409871 |
2018 |
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the ability of ustekinumab, a monoclonal antibody against the p40 subunit of interleukins 12 and 23, to induce endoscopic healing in patients with moderate to severe Crohn's disease (CD).
|
29909019 |
2018 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The introduction of ustekinumab, an interleukin [IL]12/23 p40 inhibitor, to the therapeutic armamentarium of Crohn's disease has provided a much needed treatment option for patients who have failed conventional biologics with anti-tumour necrosis factor [TNF] and anti-integrin agents.
|
30169620 |
2018 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab is an interleukin inhibitor which blocks the p40 subunit of IL-12 and IL-23 axis and is already approved for the treatment of Crohn's disease patients, specially those who had inadequate response or intolerance to conventional treatment with anti-TNF-α agents.
|
29846261 |
2018 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lastly, ustekinumab, a monoclonal antibody (mAb) to the p40 subunit of IL-12 and IL-23, has showed good efficacy and safety profile in patients with Crohn's disease (CD).
|
30060945 |
2018 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated the proinflammatory role of IL9 in the colonic mucosa of patients with CD.
|
29788092 |
2018 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum IL9 as well as other cytokines (IL1β, IL6, IL13, IFNγ, TNFα, and VEGF-A) were determined in 293 individuals: 97 patients with Crohn's disease (CD) and 74 with ulcerative colitis (UC) and in 122 apparently healthy controls.
|
28652656 |
2017 |
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The serum IL-9 levels were significantly higher in the patients with active CD (22.0 pg/mL) than in the control individuals (6.3 pg/mL) (P < 0.001); they differed according to disease severity (moderate-to-severe CD: 29.1 pg/mL versus mild CD: 12.9 pg/mL) (P < 0.001), and they correlated well with the clinical activity of CD.
|
28644181 |
2017 |
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ustekinumab, an inhibitor of the p40 subunit of interleukins 12 and 23, is an effective treatment for patients with Crohn's disease (CD).
|
28365485 |
2017 |
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Unlike AS and CD, a strong and significant up-regulation of IL-9 was observed in PsA gut, especially among infiltrating mononuclear cells, high endothelial venules, and Paneth cells.
|
26895441 |
2016 |
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Two monoclonal antibodies neutralizing the p40 chain (ustekinumab and briakinumab) and hence blocking both IL-12 and IL-23 activity, have been developed, which demonstrated clinical benefit in early phase trials, and hinted towards efficacy in a subpopulation of patients with CD who had failed prior anti-TNF antibody treatment.
|
24138637 |
2013 |
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms within the genes encoding the IL-12 p40 subunit, IL12B, and one of the IL-23 receptor subunits, IL23R, have been replicated in US and European populations and overlap with risk of Crohn's disease.
|
18830267 |
2009 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, the recently described IL-23 shares the p40 subunit with IL-12, raising the possibility that the clinical benefit of the anti-IL-12/p40 antibody in CD may also be due to the neutralization of IL-23 activity.
|
17007011 |
2006 |
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated whether a TaqI polymorphism in the 3'UTR of the IL-12 p40 gene affects secretion of IL-12 in vitro, and whether this polymorphism is associated with susceptibility to Crohn's disease (CD).
|
12424624 |
2002 |
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IL-12 p40 expression in CD is heterogeneous.
|
11515847 |
2001 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-12 p35 and p40 antisense probes were used to examine ileal specimens from 9 children with CD and gastric biopsies from 24 children (13 with CD, 6 with Helicobacter pylori chronic gastritis, and 5 with a normal gastric mucosa).
|
9502407 |
1998 |